Work

Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model

Year: 2011

Type: article

Abstract: Diabetes is a major risk factor for left ventricular dysfunction with cardiac and renal fibrosis. C-type natriuretic peptide (CNP) is a 22 amino-acid peptide produced mainly in the cardiac endothelium with potent cardiac unloading, anti-fibrotic and antihypertensive effects, but minimal renal actions. Using this knowledge we designed a natriuretic peptide CBA-NP by fusing a 6 AA sequence (KVLRRH) from BNP to the C-terminus and a 5 AA sequence (RMDRI) from ANP to the N-terminus of CNP to enhance beneficial renal effects while maintaining CNP’s inherent cardioprotective properties.

Source: BMC Pharmacology

DOI: 10.1186/1471-2210-11-s1-p2

Authors: Syed Ameenuddin, Elise A Oehler, John C Burnett, Horng H Chen

Institution: Mayo Clinic

Language: English

Topic: Cardiac Fibrosis and Remodeling

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W2058106960

FWCI:

Cites:

Cited by:

Related to: 10